About Gilead Sciences
Industry:
Biotechnology
Founded:
1987
Founders:
Michael Riordan
Status:
Public (NASDAQ: GILD)
Funding & Growth
Total Raised:
N/A
Valuation:
$100B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Leader in HIV and antiviral therapies
- • Strong financials and cash position
- • Foster City/Bay Area location
- • Excellent compensation and benefits
- • Growing oncology pipeline (Kite)
✗ Cons
- • HIV franchise maturity concerns
- • Some restructuring in recent years
- • Large company processes
- • Competition in key therapeutic areas